Read the story here. Advertise at Before It's News here.
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views
Last hour:
Last 24 hours:

VolitionRx says Nu.Q NETs assay shows promising results in coronavirus risk stratification

% of readers think this story is Fact. Add your two cents.

VolitionRx Limited said it has been working with researchers at two leading NHS Foundation Trusts on studies in coronavirus (COVID-19) for which abstracts were released this week at the International Society on Thrombosis and Haemostasis (ISTH) Congress, in Philadelphia.

The Austin, Texas-based epigenetics company’s easy-to-use blood-based Nu.Q test has been found to be an effective method for monitoring Neutrophil Extracellular Traps (NETs) in sepsis. Significantly, NETs also play a role in COVID-19, autoimmune diseases, and cancer.

In a statement, Volition Chief Scientific Officer Dr Jake Micallef said: “We believe our Nu.Q NETs assay will have wide applicability for monitoring diseases with a NETs component such as COVID-19, sepsis, autoimmune diseases and cancer and potentially to risk stratify patients for treatment selection.”

READ: VolitionRx’s Nu.Q cancer-screening blood tests could replace colonoscopies, biopsies

“We have further large studies in progress in COVID-19, sepsis and other diseases as well as studies in potential use as a companion diagnostic in sepsis. I look forward to the completion of ongoing studies and the publication of further data in the coming months,” he added.

Volition earlier reported preliminary results demonstrating that its Nu.Q NETs assay correlated well with COVID-19 disease severity. The firm now reports “early-stage data” with the same assay showing that results on admission could “predict future COVID-19 disease severity and that serial results correlate with disease progression.

While commenting on the poster presentation titled Circulating Nucleosomes Immunoassay: Evaluating a Clinically Applicable Test to Risk Stratify COVID-19 and Target Anticoagulation, lead author and hematologist Dr Catherine Rea said: “The Nu.Q NETs biomarker results taken on hospital admission in this study corelated with COVID-19 disease severity and were predictive of whether patients required care in a general ward or organ support in an intensive care ward.”

“The study results also indicated that elevated values of Nu.Q H3.1 could predict poor outcomes in patients admitted to Intensive Care, including an association with 28-day mortality, and may be of value in risk stratifying patients for treatments such as therapeutic anticoagulation, as well as in monitoring patient response to treatment.”

Similarly, while commenting on the poster titled Identifying Tools to Track Hypercoagulability in COVID-19 Patients, lead author and scientist Dr Sophia Stanford said: “While this is a small exploratory study, the Nu.Q NETs H3.1 biomarker values closely tracked the clinical course of COVID-19 patients admitted directly to Intensive Care, admitted to a general ward or admitted to a general ward and then transferred to Intensive Care during their hospital stay.”

“These findings suggest the Nu.Q H3.1 assay may be able to risk stratify COVID-19 patients on admission and monitor disease progression in individual patients.”

To view the poster by Dr Rea click here and to view the poster by Dr Stanford click here.

Volition’s tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present.

Contact the author Uttara Choudhury at [email protected]

Follow her on Twitter: @UttaraProactive

Story by ProactiveInvestors


Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world.

Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.

"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.

Please Help Support BeforeitsNews by trying our Natural Health Products below!

Order by Phone at 888-809-8385 or online at M - F 9am to 5pm EST

Order by Phone at 888-388-7003 or online at M - F 9am to 5pm EST

Order by Phone at 888-388-7003 or online at M - F 9am to 5pm EST

Humic & Fulvic Trace Minerals Complex - Nature's most important supplement! Vivid Dreams again!

HNEX HydroNano EXtracellular Water - Improve immune system health and reduce inflammation

Ultimate Clinical Potency Curcumin - Natural pain relief, reduce inflammation and so much more.

MitoCopper - Bioavailable Copper destroys pathogens and gives you more energy. (See Blood Video)
Oxy Powder - Natural Colon Cleanser!  Cleans out toxic buildup with oxygen! 
Nascent Iodine - Promotes detoxification, mental focus and thyroid health.
Smart Meter Cover -  Reduces Smart Meter radiation by 96%!  (See Video)

Immusist Beverage Concentrate - Proprietary blend, formulated to reduce inflammation while hydrating and oxygenating the cells.

Report abuse


    Your Comments
    Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

    Load more ...




    Email this story
    Email this story

    If you really want to ban this commenter, please write down the reason:

    If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.